science wire

« BACK

Pharmacology



Results 1151 - 1200 of 1424.


Health - Pharmacology - 17.01.2013
Novartis makes progress in the fight to eliminate leprosy worldwide
Novartis advances goals set as part of a coordinated, international effort to eliminate or control 10 neglected tropical diseases (NTDs) Over 500 facilities in Tanzania now use SMS for Life to track

Health - Pharmacology - 14.01.2013
Pivotal study in The Lancet shows potential of Novartis vaccine Bexsero to help provide broad protection to infants against MenB
Phase III results show that Bexsero induced a robust immune response when administered concomitantly with routine vaccines, and also as a booster dose Data confirm Bexsero's acceptable safety and tolerability profile in infants, who are among the most vulnerable to MenB, a leading cause of meningitis Bexsero was recommended for European licensure in November 2012; upon approval, Bexsero will be the first and only broad coverage vaccine against M

Health - Pharmacology - 11.01.2013
Phase III data in The Lancet show significant benefit of Novartis drug Afinitor in patients with non-cancerous tumors associated with TSC
More than 40% of TSC patients on everolimus had their kidney tumor volume reduced by at least half with no tumor progression Separate data show 35% of TSC patients treated with everolimus had their SEGA brain tumor volume reduced by one half or more Tuberous sclerosis complex (TSC), a genetic disorder, may cause non-cancerous tumors to form in vital organs, including the kidney and brain Basel, January 10, 2013 - Data published today in The Lanc

Pharmacology - Life Sciences - 03.01.2013
How stabilised cell fibres prevent cancer cell division
How stabilised cell fibres prevent cancer cell division
Media Releases Human Health Biology Research Using Synchrotron Light Detailed structural information provides the foundation for new drugs Anti-cancer drugs used under the heading of "Chemotherapy” prevent cells from dividing. As the cells in a growing tumour divide more frequently than others, tumour cells in particular are highly damaged by chemotherapeutic drugs.

Health - Pharmacology - 21.12.2012
Novartis drug Exjade approved by European Commission
Novartis drug Exjade approved by European Commission for iron overload in patients with non-transfusion-dependent thalassemia Exjade is the first oral treatment approved in the EU for chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate At least thr

Health - Pharmacology - 15.12.2012
Novartis drug Signifor gains FDA approval as the first medication to treat Cushing’s disease, a serious endocrine disorder
As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease In the Phase III trial, most patients experienced

Health - Pharmacology - 11.12.2012
Combination therapy for incurable metastatic breast cancer to circumvent therapy resistance
Scientists discovered how resistance mechanisms arise during the treatment of incurable metastatic breast cancer and suggest strategies to circumvent these by a combination therapy. Triple-negative breast cancers are the bad guys among the different types of breast cancer. They affect younger women, metastasize more easily, are tougher to treat and once treated become therapy resistant faster.

Pharmacology - Health - 11.12.2012
Two-year data show new Novartis drug Jakavi significantly reduced myelofibrosis disease burden and suggest overall survival advantage
Jakavi demonstrated rapid reductions in spleen size and improved quality of life in Phase III studies, with results sustained over two years COMFORT-II follow-up results show Jakavi may improve overall survival vs.

Pharmacology - Health - 10.12.2012
Novartis long-term Phase III data show Ph+ CML patients on Tasigna achieved significantly deeper molecular response versus Glivec
Both newly diagnosed patients and those switching to Tasigna after long-term treatment with Glivec achieved deeper molecular response with Tasigna Data suggest correlation between early molecular res

Health - Pharmacology - 04.12.2012
Roche and the US President’s Emergency Plan for AIDS Relief (PEPFAR) partner to strengthen laboratories medicine training and knowledge on the African continent
Roche and the US President's Emergency Plan for AIDS Relief (PEPFAR) partner to strengthen laboratories medicine training and knowledge on the African continent Today Roche Diagnostics and the US Pre

Health - Pharmacology - 28.11.2012
Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
Long-term follow-up data from Jakavi Phase III trials in patients with the debilitating blood cancer, myelofibrosis Updated Phase III data in patients with Ph+ CML who switched to Tasigna after long

Health - Pharmacology - 20.11.2012
Novartis receives FDA approval for Flucelvax , the first cell-culture vaccine in US to help protect against seasonal influenza
Cell-culture technology, an alternative to traditional egg-based production, is the most significant advancement in influenza vaccine manufacturing in more than 40 years Flucelvax is the only influen

Health - Pharmacology - 16.11.2012
Novartis receives positive CHMP opinion for Bexsero
Meningococcal serogroup B (MenB) disease is easily misdiagnosed, can kill within 24 hours and may cause serious, life-long disabilities , Upon approval, Bexsero will be the first and only broad cover

Health - Pharmacology - 16.11.2012
Novartis drug Exjade recommended by CHMP for EU approval to treat patients with non-transfusion-dependent thalassemia syndromes
Exjade would be the first oral treatment approved specifically for patients with non-transfusion-dependent thalassemia (NTDT) syndromes Clinical data show Exjade significantly decreases iron burden in NTDT patients compared to placebo, with similar overall adverse event rate NTDT patients accumulate excess iron, increasing their risk of complications, including liver fibrosis, cirrhosis, blood clots and bone and vascular disease Basel, November

Pharmacology - Health - 12.11.2012
Novartis new two-year data with Certican shows positive outcomes at 24 months in largest liver transplant trial to date
Study's endpoints met; Certican with reduced exposure tacrolimus provided comparable efficacy with superior renal function maintained from month one to 24 versus control arm Calcineurin inhibitors li

Health - Pharmacology - 11.11.2012
Novartis data show ACZ885 delivered rapid and strong symptom relief while reducing frequency of attacks in two periodic fever syndromes
New Phase II study shows monthly ACZ885 reduced attack frequency by >= 50% and normalized inflammation markers in Familial Mediterranean Fever patients ACZ885 also provided sustained symptom relie

Pharmacology - Health - 08.11.2012
Novartis future growth prospects secured by industry-leading pipeline, with more than 139 projects with 73 new compounds
Pharmaceuticals Division growth over the next 5 years expected to be driven by portfolio of recently launched products Division had 7 blockbusters in portfolio in 2011 and expects to achieve 14 or mo

Health - Pharmacology - 07.11.2012
Novartis drug Signifor recommended by FDA advisory committee for approval to treat patients with Cushing’s disease
Committee votes unanimously in favor of Signifor (pasireotide) as the first medication to treat US patients with Cushing's disease Pasireotide represents the first targeted approach for this potentia

Pharmacology - Health - 07.11.2012
RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
RELAX-AHF study met one of its two primary endpoints in reducing dyspnea or shortness of breath, and was therefore positive under pre-specified criteria Newly presented data show that at six months, RLX030 reduced all-cause and cardiovascular mortality by 37% in patients with acute heart failure (AHF) RLX030 is the first in a new class of medicines and the only agent to show a reduction in mortality in AHF Nearly a quarter of patients with AHF c

Health - Pharmacology - 06.11.2012
Sensimed Raises 17 Million CHF
Specializing in the diagnosis of glaucoma, a spin-off of EPFL has just completed a major round of financing which should enable it, among other things, to penetrate the American and Chinese markets.

Health - Pharmacology - 05.11.2012
Novartis drug Votubia approved in the EU
Prior to this approval, surgical intervention was the only option in Europe for these tuberous sclerosis complex (TSC) patients , Kidney tumors, or renal angiomyolipomas, affect up to 80% of patients

Health - Pharmacology - 31.10.2012
Roche medicine Avastin receives EU approval for the treatment of women with recurrent, platinum-sensitive ovarian cancer
Avastin is the first biological therapy approved for newly diagnosed and recurrent ovarian cancer Roche announced today that the European Commission (EC) has approved Avastin (bevacizumab) in combina

Pharmacology - Health - 31.10.2012
Novartis to start construction of new biotechnology facility in Singapore with an investment of over USD 500 million
Investment supports growing pipeline of biologics portfolio representing 25% of current clinical pharmaceutical research pipeline Singapore will operate as a technological competence center for biote

Pharmacology - Health - 12.10.2012
New analysis indicates that Novartis drug Gilenya shows significant early effect on reducing brain volume loss at 6 months
New analysis of two large Phase III studies demonstrates a significant early treatment effect of Gilenya on relapses and MRI outcomes, including brain volume loss, in MS patients Data show generally higher adherence rates for once-daily oral Gilenya than injectable DMTs and positive real-world experience Pooled analysis of core and long-term study data from over 3,500 patients reinforce known safety profile; more than 49,000 patients treated as

Pharmacology - Health - 01.10.2012
Novartis receives European Commission approval for once-daily Seebri Breezhaler as maintenance COPD treatment in the EU
Seebri Breezhaler 44 mcg delivered dose approved for maintenance treatment of COPD will be available to patients and physicians in some EU markets by year-end In GLOW trials, Seebri Breezhaler improved lung function, reduced shortness of breath, reduced exacerbations, and improved quality of life up to 52 weeks versus placebo , , GLOW2 study showed Seebri Breezhaler provided 24-hour bronchodilation and is superior to placebo and similar to open

Health - Pharmacology - 27.09.2012
Novartis data show AIN457 significantly reduced signs and symptoms in patients with hard-to-treat moderate-to-severe plaque psoriasis
Phase II data show AIN457 given weekly during the first month of treatment improved hand/foot psoriasis at Week 12 (54% of patients vs 19% on placebo) AIN457 selectively binds to and inhibits interleukin-17A, a key driver of immune-mediated diseases and a promising target for the next generation of therapy[2-4] AIN457 pivotal Phase III trials with more than 3,000 psoriasis patients on track with regulatory submissions expected in 2013 Psoriasis

Health - Pharmacology - 24.09.2012
Results from Novartis Phase III study show that RLX030 reduced deaths in patients with acute heart failure
RELAX-AHF study met one of its two primary endpoints in reducing dyspnea or shortness of breath, and showed RLX030 (serelaxin) was well tolerated Six-month study shows that investigational RLX030 reduced all-cause mortality in patients with acute heart failure (AHF) Results of single Phase III clinical trial to be discussed with health authorities worldwide Basel, September 24, 2012 - Phase III study results show that investigational RLX030 (serelaxin) reduced all-cause mortality in patients with acute heart failure (AHF) .

Health - Pharmacology - 21.09.2012
Novartis announces two CHMP positive opinions
Positive opinion for the use of vildagliptin, with or without metformin, in combination with a stable dose of insulin Additional positive opinion for the use of vildagliptin in combination with a sul

Health - Pharmacology - 21.09.2012
Novartis drug Votubia recommended by CHMP for EU approval
Votubia (everolimus) would be the first non-surgical treatment option in the EU for kidney tumors associated with tuberous sclerosis complex (TSC) Kidney tumors, or renal angiomyolipomas, affect up t

Health - Pharmacology - 05.09.2012
New data for Novartis drug Lucentis confirms long-term efficacy and safety profile and benefits of individualized treatment
REPAIR study shows an average of three Lucentis injections improve visual acuity in patients with myopic choroidal neovascularization RESTORE extension study demonstrates DME patients fully maintained initial vision gains with an average of 13.9 Lucentis injections over three years Retrospective analysis reinforces Lucentis well-characterized safety profile in wet AMD; ongoing LUMINOUS TM program now involves over 10,000 patients Basel, S

Pharmacology - Health - 03.09.2012
Novartis data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA149
QVA149 demonstrated superior bronchodilation compared to indacaterol 150 mcg, glycopyrronium 50 mcg, salmeterol/fluticasone 50/500 mcg BID, OL tiotropium 18 mcg and placebo , Seebri Breezhaler (glycopyrronium bromide) demonstrated rapid, sustained bronchodilation and reduced exacerbations similar to OL tiotropium 18 mcg in GLOW pooled data analysis , Onbrez Breezhaler (indacaterol maleate) was superior to OL tiotropium 18 mcg in improving severe

Pharmacology - Health - 30.08.2012
Novartis QVA149 Phase III study meets primary endpoint in reducing exacerbations in COPD patients, filing in EU and Japan by end of year
SPARK demonstrated QVA149 statistically significantly reduced rate of moderate-to-severe exacerbations compared to glycopyrronium 50 mcg Study showed QVA149 statistically significantly reduced overall exacerbation rates compared to glycopyrronium 50 mcg and open-label tiotropium 18 mcg Basel, August 30, 2012 - Novartis announced today that the fifth QVA149 (indacaterol maleate / glycopyrronium bromide) Phase III study, SPARK, met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide (Seebri Breezhaler ) .

Pharmacology - Health - 29.08.2012
Novartis International BioCamp Highlights Global R&D Reach to Meet Patient Needs in Emerging Markets
International e vent brings 60 university students from 21 countries and territories to Novartis headquarters in Basel, Switzerland Dynamic BioC amp program engages students around scientific advance

Pharmacology - Health - 28.08.2012
Novartis drug Jakavi first medication to receive European Commission approval to treat patients with myelofibrosis
Jakavi (INC424, ruxolitinib) approval based on results from the most extensive myelofibrosis clinical trial program to date Myelofibrosis is a life-threatening blood cancer associated with progressiv

Pharmacology - Health - 26.08.2012
New Novartis Phase II data show LCZ696 may provide clinical benefits in patients with a difficult-to-treat form of heart failure
PARAMOUNT study shows LCZ696 reduced a key predictor of morbidity and mortality in patients with a common form of heart failure called HF-PEF , Up to half of the 20 million Europeans and Americans diagnosed with heart failure have HF-PEF - , leading to reduced life expectancy and frequent hospitalization - No therapies are currently approved to reduce morbidity and mortality in patients with HF-PEF, or heart failure with preserved ejection fract

Health - Pharmacology - 15.08.2012
Phase III results published in NEJM show ocriplasmin could be first pharmacological eye treatment for vitreomacular adhesion patients
Vitreomacular adhesion is an age-related progressive, debilitating eye disease, often leading to blindness; standard of care is "watchful waiting" or surgery Phase III results show that ocriplasmin significantly (p<0.001) resolved vitreomacular traction and closed macular holes compared to placebo For the majority of patients with resolution of vitreomacular adhesion after ocriplasmin administration, the resolution was achieved within

Health - Pharmacology - 06.08.2012
Novartis and University of Pennsylvania form broad-based R&D alliance to advance novel T-cell immunotherapies to treat cancer
Novartis and Penn enter into multi-year collaboration to study chimeric antigen receptor (CAR) technology for the treatment of cancer Pilot trial of first CAR investigational therapy, CART-19, shows two patients with advanced chronic lymphocytic leukemia in remission after more than a year , Novartis licenses worldwide rights to CART-19 from Penn and obtains worldwide commercial rights to products from the collaboration Basel, August 6, 2012 - N

Health - Pharmacology - 30.07.2012
Novartis drug Afinitor approved by European Commission to treat patients with the most common form of advanced breast cancer
In combination with exemestane, Afinitor is approved for use in women with HR+/HER2- advanced breast cancer after progressing on an aromatase inhibitor Approval is based on Phase III trial of more th

Health - Pharmacology - 20.07.2012
Novartis gains FDA approval for Afinitor in advanced breast cancer marking a significant milestone for women battling this disease
Approval represents the first major advance for US patients with advanced HR+ breast cancer since aromatase inhibitors were introduced more than 15 years ago In a Phase III trial, Afinitor plus exeme

Pharmacology - Life Sciences - 25.06.2012
A new dimension for cell culture
The system developed by QGel allows for new tests of anti-cancer medication and novel experimentation in tissue engineering and regenerative medicine. Cancer cells and stem cells can now be cultivated in 3 dimensions to serve in various experiments to great advantage for researchers. This matrix, commercialized by the start-up QGel, which is based in the scientific park at Ecublens, offers the cells a similar environment to a living organism and is adaptable to the needs of the researcher.

Health - Pharmacology - 22.06.2012
Novartis receives positive CHMP opinion for once-daily Seebri Breezhaler to treat COPD patients in the EU
COPD patients in Phase III GLOW trials experienced improved lung function, reduced shortness of breath, reduced exacerbations, and improved quality of life , , , GLOW2 study showed Seebri Breezhaler provided 24-hour bronchodilation and was superior to placebo and similar to open-label tiotropium in improving lung function Seebri Breezhaler is the latest innovation in the Novartis COPD portfolio and when approved will offer patients an alternativ

Health - Pharmacology - 22.06.2012
CHMP recommends Novartis drug Afinitor for EU approval marking major milestone in the treatment of advanced breast cancer
Upon approval, Afinitor will provide a new treatment approach for women with HR+ advanced breast cancer, where there remains a significant unmet need In a Phase III trial, women taking Afinitor with

Pharmacology - Health - 22.06.2012
New data from Phase III study showed that people with HER2-positive metastatic breast cancer lived longer with Roche’s Perjeta
Basel, June 22, 2012   New data from Phase III study showed that people with HER2-positive metastatic breast cancer lived longer with Roche's Perjeta Roche announced today that people with HER-2 posi

Pharmacology - Health - 11.06.2012
FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer
Basel, 11 June, 2012 FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer New personalised medicine gives people with aggressive form of breast cancer more time wi

Pharmacology - Health - 11.06.2012
Novartis drug Gilenya shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
Data from single-arm extension of head-to-head TRANSFORMS study show sustained reduction in relapses and rate of brain volume loss in patients on continuous Gilenya treatment for up to 4.5 years Reductions in relapses and MRI measures were observed in patients who switched from Avonex (interferon-beta-1a IM) to Gilenya for study extension phase Extension study results demonstrated once-daily oral Gilenya was generally well-tolerated with

Health - Pharmacology - 06.06.2012
Novartis Phase III study showed 62% of patients with most severe form of childhood arthritis were symptom-free with ACZ885 treatment
Data also showed one third of patients became steroid-free within five months with ACZ885 , a fully human monoclonal antibody that inhibits IL-1 beta ACZ885 regulatory submissions on track for 2012 i

Health - Pharmacology - 31.05.2012
Novartis showcases ongoing research at ASCO to help patients fight various cancers, including updated data in advanced breast cancer
18-month BOLERO-2 data confirm Afinitor combined with exemestane delays time without tumor growth for women with HR+ advanced breast cancer Data highlighted by ASCO show twice as many Ph+ CML-CP patients achieved deeper levels of response with Tasigna compared to imatinib , Earl y data on pipeline compounds demonstrate potential in breast cancer, non-small cell lung cancer, NRAS-mutated melanoma and other solid tumors Basel, May 31, 2012 - Novar

Pharmacology - Health - 17.05.2012
Novartis NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD patients
GLOW2 study showed NVA237 superior to placebo and similar to open-label tiotropium in increasing lung function, improving COPD symptoms and reducing exacerbations , , Results demonstrated that once-daily NVA237 had rapid onset of action at first dose, sustained 24-hour bronchodilation, and was well tolerated over 52 weeks NVA237 submitted for EU approval under proposed brand name Seebri Breezhaler ; expect US filing in 2014 COPD is predicted to

Pharmacology - Health - 10.05.2012
New data among 200 Lucentis abstracts at ARVO show low number of injections with Novartis drug required to achieve and maintain vision gains over 3 years in AMD and DME patients
Data from key studies highlight the value of individualized therapy and reinforce Lucentis (ranibizumab) well-characterized long-term efficacy and safety profile RESTORE extension study in DME patients shows mean of 3.7 and 2.7 Lucentis injections required in years two and three, respectively, to maintain vision gains from core study Swiss retrospective study shows mean 8 letter VA gain sustained in wet AMD patients using individua

Health - Pharmacology - 07.05.2012
Novartis drug pasireotide LAR shows superior efficacy
Patients on pasireotide (SOM230) LAR were 63% more likely to achieve full biochemical control than those on Sandostatin LAR, the current standard of care Acromegaly, a rare endocrine disorder caused

This site uses cookies and analysis tools to improve the usability of the site. More information. |